LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First Saliva Diagnostic Test for Endometriosis Delivers Reliable Results Within Days

By LabMedica International staff writers
Posted on 12 Feb 2025

Endometriosis affects approximately 1 in 10 women globally, with a range of symptoms that can severely impact their health, quality of life, and fertility. The delay in diagnosis, which can take between 7 to 10 years, is a significant barrier to improving care, life quality, and fertility outcomes. Now, a pioneering saliva-based diagnostic test for endometriosis offers new possibilities for early and non-invasive diagnosis of this painful disease.

The Ziwig Endotest, developed by Ziwig (Lyon, France), is a saliva test for endometriosis that provides a reliable diagnosis within just a few days. Ziwig is transforming the diagnosis and treatment of women's health conditions by harnessing the power of salivary RNA. The Ziwig Endotest is the first-ever application of salivary microRNA1-6 in gynecology. This test requires only a simple saliva sample, with the diagnosis performed in the laboratory. It is based on high-throughput sequencing of the microRNA found in saliva, combined with artificial intelligence (AI) to process the large volumes of data generated. Using the Ziwig Endotest, a diagnosis can be made in just a few days with exceptional accuracy (97.4% sensitivity, 93.7% specificity). The test enables clinicians to reliably confirm or exclude a diagnosis of endometriosis and distinguish it from other conditions with similar symptoms. It is particularly useful in complex cases where medical imaging may be inconclusive.


Image: The saliva test for endometriosis provides a reliable diagnosis within just a few days (Photo courtesy of Ziwig)
Image: The saliva test for endometriosis provides a reliable diagnosis within just a few days (Photo courtesy of Ziwig)

Ziwig’s non-invasive approach to saliva sampling, along with technological advancements in sequencing and AI, makes accurate, early diagnosis of endometriosis more accessible. The company’s focus on the RNA and extracellular vesicles in saliva represents a milestone in personalized medicine. The Ziwig Endotest offers a breakthrough biological test for healthcare providers and patients by reducing diagnostic delays, identifying complex and early-stage cases sooner, providing an alternative to invasive procedures, and enhancing fertility preservation through earlier diagnosis.

"With Ziwig Endotest we are determined to end the unacceptable diagnostic wandering that leaves many women in pain,” said Yahya El Mir, Ziwig CEO-Founder.

Related Links:
Ziwig


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Hemodynamic System Monitor
OptoMonitor
New
Gold Member
Hematology Analyzer
Medonic M32B

Latest Molecular Diagnostics News

2-Hour Cancer Blood Test to Transform Tumor Detection
12 Feb 2025  |   Molecular Diagnostics

Ultrasensitive Test Could Identify Earliest Molecular Signs of Metastatic Relapse in Breast Cancer Patients
12 Feb 2025  |   Molecular Diagnostics

Automated High Throughput Immunoassay Test to Advance Neurodegenerative Clinical Research
12 Feb 2025  |   Molecular Diagnostics